X-Biotix Therapeutics

X-Biotix Therapeutics specializes in the development of novel small molecule antibiotic scaffolds for multi-drug resistant (MDR) gram-negative pathogens to address the urgent and growing global threat of antibiotic resistance. It applies a multi-target strategy to generate a pipeline of effective antibiotics with inhibitory activity against a wide range of biological targets in essential pathways of gram-negative bacterial cells and which are also predicted to defeat known antibiotic resistance mechanisms. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.